Yabao Pharmaceutical Group (600351.SH): has repurchased a total of 0.75% of its shares.

Gelonghui December 2nd, yabao pharmaceutical group (600351.SH) announced that as of November 30, 2024, the company has repurchased a total of 5,419,097 shares through centralized competitive bidding trading, accounting for 0.75% of the total share capital of the company. The highest fill price for repurchase is 6.56 yuan/share, and the lowest fill price is 5.87 yuan/share, with a total amount paid of RMB 33,948,400.49 (excluding transaction fees).

Gelonghui FinanceDec 2, 2024 16:09

Yabao Pharmaceutical Group Gets Registration Certificate for Oral Solution

MT NewswiresNov 22, 2024 15:31

Express News | Yabao pharmaceutical group: Subsidiary obtains the registration certificate for the oral solution of ambroxol.

BreakingsNov 21, 2024 16:02

yabao pharmaceutical group saw a year-on-year increase in revenue for two children's medications. Revenue for the injection of Benatuostin hydrochloride has not yet stopped declining. | Directly focusing on the earnings conference

At the earnings conference, yabao pharmaceutical group stated that in the first three quarters of this year, the company's pediatric products revenue increased year-on-year. The company's secretary of the board also mentioned that while the revenue of Tenatoprazole Hydrochloride Injection decreased, sales volume increased, and predicted that the 'income decline in this category will continue to narrow within the year'. yabao pharmaceutical group also provided explanations on the progress of the company's R&D pipeline, share buybacks, and other situations.

cls.cnNov 12, 2024 12:48

Express News | Yabao Pharmaceutical Group established a new biomedical company with 80 million yuan.

BreakingsNov 5, 2024 14:12

Yabao Pharmaceutical Group Co., Ltd. Report for the Third Quarter of 2024 (Revised Edition)

SZSIOct 26, 2024 00:00 · Announcements